DRUG DISCOVERY AND DIAGNOSTICS BY FORCE SPECTROSCOPY

Information

  • Research Project
  • 2718064
  • ApplicationId
    2718064
  • Core Project Number
    R43RR013529
  • Full Project Number
    1R43RR013529-01
  • Serial Number
    13529
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1998 - 26 years ago
  • Project End Date
    3/31/1999 - 25 years ago
  • Program Officer Name
    BEISLER, JOHN A.
  • Budget Start Date
    9/1/1998 - 26 years ago
  • Budget End Date
    3/31/1999 - 25 years ago
  • Fiscal Year
    1998
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/31/1998 - 26 years ago

DRUG DISCOVERY AND DIAGNOSTICS BY FORCE SPECTROSCOPY

The goal of this SBIR Phase I proposal is to develop force spectroscopy (F-SPEC) as a tool for drug discovery and high throughput molecular screening and analysis. F-SPEC is based on direct measurement of molecular interactions using an ultra-sensitive biosensor created by biomolecular functionalization of an Atomic Force Microscope (AFM) probe. Phase I will focus on the G-protein Ras, a key protein in 30% of all cancers. Farnesylation of Ras is required before it can associate with the membrane for signal transduction, making competitive inhibitors of farnesyl transferase (FT,) attractive as cancer fighting drugs. Specific Aim 1 is to show by F-SPEC that a difference in the interaction between Ras and farnesyl transferase (FTase) can be measured while an inhibitor is present versus absent Abnormal Ras GTPase activity is often related to mutations involved in oncogenesis. Specific Aim 2 is to develop a method using F-SPEC to distinguish wild-type from mutant Ras based upon binding interactions with GTPase Activating Proteins (GAPs) in the presence or absence of GTP. If Phase I is successful, F-SPEC will be implemented as a high throughput drug discovery and molecular diagnostic technology in Phase II and beyond. PROPOSED COMMERCIAL APPLICATIONS: The technology to be developed in this research program will provide a rapid and ultra-sensitive method for screening potentially useful compounds as drugs, and for testing differences in wt and mutant gene products involved in cancer and other diseases.

IC Name
NATIONAL CENTER FOR RESEARCH RESOURCES
  • Activity
    R43
  • Administering IC
    RR
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    371
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG3
  • Study Section Name
  • Organization Name
    BIOFORCE NANOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
    879345213
  • Organization City
    AMES
  • Organization State
    IA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    50010
  • Organization District
    UNITED STATES